J Menopausal Med.  2017 Aug;23(2):131-134. 10.6118/jmm.2017.23.2.131.

Metachronous Cancer of Breast and Adenocarcinoma of Cervix: A Rare Case Report

• Sharma N
• Thiek JL
• Rituparna
• Mishra J
• Singh AS

• KMID: 2389229
• DOI: http://doi.org/10.6118/jmm.2017.23.2.131

Abstract

The occurrence of a second primary cancer in a cancer survivor is well documented. It may be synchronous or metachronous. Incidence of metachronous cancer involving cervix is 0.82% to 1.33%. One such metachronous cancer is that of breast and cervix. We present a case of a woman who received tamoxifen for invasive ductal cancer of breast following a modified radical mastectomy and subsequently developed adenocarcinoma of cervix after six month of tamoxifen therapy. The role of tamoxifen in pathogenesis of cervical cancer and that of human papillomavirus infection in pathogenesis of both cancer of cervix and breast cancer has been well recognized. In our patient, the adenocarcinoma of cervix (rare occurrence) which is likely due to six month of tamoxifen therapy is a perplexing question. Women diagnosed and treated for breast cancer need to be followed up for development of other metachronous gynecological cancers.

Keyword

Cervical cancer; Metachronous cancer; Tamoxifen Breast cancer

MeSH Terms

Adenocarcinoma*
Breast
Breast Neoplasms*
Cervix Uteri*
Female
Humans
Incidence
Mastectomy, Modified Radical
Neoplasms, Second Primary
Papillomavirus Infections
Survivors
Tamoxifen
Uterine Cervical Neoplasms
Tamoxifen

Figure

• 

  Fig. 1 Hematoxylin and eosin at 20× shows cells are arranged in nests and occasional duct like structure and solid clusters suggestive of invasive ductal carcinoma-NOS.

• 

  Fig. 2 Hematoxylin and eosin at 20× shows back to back glandular pattern of tubules, papillae and glands with features of moderately differentiated adenocarcinoma of cervix.

Reference

1. Takatori E, Shoji T, Miura Y, Takeuchi S, Uesugi N, Sugiyama T. Triple simultaneous primary invasive gynecological malignancies: a case report. J Obstet Gynaecol Res. 2014; 40:627–631.

2. Watrowski R, Striepecke E, Jäger C, Bauknecht T, Horst C. Papillary-serous adenocarcinoma of the uterine cervix during tamoxifen therapy after bilateral breast cancer. Anticancer Res. 2012; 32:5075–5078.

3. Muss HB. Role of adjuvant endocrine therapy in early-stage breast cancer. Semin Oncol. 2001; 28:313–321.

4. De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G, De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet. 1991; 36:127–130.

5. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet. 2000; 356:881–887.

6. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrère CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994; 343:448–452.

7. Hwang JY, Lin BY, Tang FM, Yu WC. Tamoxifen stimulates human papillomavirus type 16 gene expression and cell proliferation in a cervical cancer cell line. Cancer Res. 1992; 52:6848–6852.

8. Kim CJ, Um SJ, Kim TY, Kim EJ, Park TC, Kim SJ, et al. Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells. Int J Gynecol Cancer. 2000; 10:157–164.

9. Heng B, Glenn WK, Ye Y, Tran B, Delprado W, Lutze-Mann L, et al. Human papilloma virus is associated with breast cancer. Br J Cancer. 2009; 101:1345–1350.

10. Di Lonardo A, Venuti A, Marcante ML. Human papillomavirus in breast cancer. Breast Cancer Res Treat. 1992; 21:95–100.

11. Liu Y, Klimberg VS, Andrews NR, Hicks CR, Peng H, Chiriva-Internati M, et al. Human papillomavirus DNA is present in a subset of unselected breast cancers. J Hum Virol. 2001; 4:329–334.

12. Hennig EM, Suo Z, Thoresen S, Holm R, Kvinnsland S, Nesland JM. Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III). Breast Cancer Res Treat. 1999; 53:121–135.